دورية أكاديمية
أعرض في EDS

Brain activities of streptozotocin-induced diabetic Wistar rats treated with gliclazide: Behavioural, biochemical and histomorphology studies.

التفاصيل البيبلوغرافية
العنوان: Brain activities of streptozotocin-induced diabetic Wistar rats treated with gliclazide: Behavioural, biochemical and histomorphology studies.
المؤلفون: Ekong MB; Department of Anatomy, Faculty of Basic Medical Sciences, University of Uyo, Uyo, Nigeria., Odinukaeze FN; Department of Anatomy, Faculty of Basic Medical Sciences, University of Uyo, Uyo, Nigeria., Nwonu AC; Department of Anatomy, Faculty of Basic Medical Sciences, University of Uyo, Uyo, Nigeria., Mbadugha CC; Department of Anatomy, Faculty of Basic Medical Sciences, University of Uyo, Uyo, Nigeria., Nwakanma AA; Department of Anatomy, Faculty of Basic Medical Sciences, Chukwuemeka Odumegwu Ojukwu University, Uli, Nigeria.
المصدر: IBRO neuroscience reports [IBRO Neurosci Rep] 2022 Apr 14; Vol. 12, pp. 271-279. Date of Electronic Publication: 2022 Apr 14 (Print Publication: 2022).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101775148 Publication Model: eCollection Cited Medium: Internet ISSN: 2667-2421 (Electronic) Linking ISSN: 26672421 NLM ISO Abbreviation: IBRO Neurosci Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2021]-
مستخلص: Gliclazide (GLD), a sulphonylurea is efficacious in the treatment of diabetes type-2. However, there is limited information on its activity in the brain, especially in diabetics. This research investigated the brain activities of GLD following streptozotocin-induced diabetes in Wistar rats. Twenty five adult male Wistar rats (200-250 g) were grouped (n = 5) as: Control (distilled water, 5 mL/kg) and GLD (150 mg/kg) groups; and the diabetic groups, untreated streptozotocin (STZ, 35 mg/kg), and STZ (35 mg/kg) treated with GLD (150 mg/kg) for two and four weeks, and already on high fat diet. The animals' body weights and blood glucose levels were checked weekly. After the experimental duration, spontaneous alternation and novel object recognition tests were carried out and the animals sacrificed. Perfusion with phosphate buffered saline preceded brain excision for biochemical analyses, with halves fixed in 10% neutral buffered formalin for histology. Compared with the control, results showed (p < 0.05) declined spontaneous alternation and exploratory activities with no preference for familiar or novel objects, body weights loss, raised blood glucose, increased malondialdehyde with decreased superoxide dismutase concentrations, and no apparent adverse effect on hippocampal and prefrontal cortical Nissl substance in the untreated diabetic group. The adverse observations were attenuated in the GLD treated diabetic groups; although the spontaneous alternation in the four weeks GLD treated diabetic group improved (p < 0.05), exploration of objects increased (p < 0.05) without preference. The present results showed that treatment with GLD for two and four weeks mitigated STZ activities, even though there was less improvement in neurocognitive activities.
(© 2022 The Authors.)
References: Diabetes Ther. 2018 Jun;9(3):1307-1316. (PMID: 29761289)
Physiol Res. 2009;58(2):203-209. (PMID: 18380531)
Sci Rep. 2019 Dec 20;9(1):19556. (PMID: 31862918)
BMJ. 2016 Jul 13;354:i3625. (PMID: 27413017)
J Vis Exp. 2018 Jan 5;(131):. (PMID: 29364254)
Anal Biochem. 1978 Oct 1;90(1):81-9. (PMID: 727489)
Oxid Med Cell Longev. 2014;2014:102158. (PMID: 25215171)
Diabetes Care. 2005 Jan;28(1):71-7. (PMID: 15616236)
Curr Alzheimer Res. 2015;12(8):785-95. (PMID: 26159195)
JCI Insight. 2019 Feb 21;4(4):. (PMID: 30830866)
Am J Physiol Endocrinol Metab. 2018 Jun 1;314(6):E552-E563. (PMID: 29351480)
Nutrients. 2018 Jun 13;10(6):. (PMID: 29899272)
Hormones (Athens). 2019 Dec;18(4):523-534. (PMID: 31522366)
J Diabetes Complications. 2009 May-Jun;23(3):209-13. (PMID: 18413155)
Diabetol Metab Syndr. 2018 Apr 10;10:30. (PMID: 29651307)
J Cell Biol. 2018 Jun 4;217(6):1915-1928. (PMID: 29669742)
Biochem J. 1961 Jan;78:172-5. (PMID: 13708157)
Curr Protoc. 2021 Apr;1(4):e78. (PMID: 33905609)
J Diabetes Complications. 1994 Oct-Dec;8(4):235-9. (PMID: 7833500)
Physiol Behav. 2014 Apr 22;129:73-8. (PMID: 24582678)
Lancet Glob Health. 2013 Dec;1(6):e339-49. (PMID: 25104599)
J Neurosci Methods. 2015 Oct 30;254:73-9. (PMID: 26238727)
Drugs R D. 2004;5(4):203-8. (PMID: 15230625)
Ann N Y Acad Sci. 2015 Sep;1353:60-71. (PMID: 26132277)
PLoS One. 2014 Feb 12;9(2):e82880. (PMID: 24533045)
Metabolism. 2000 Feb;49(2 Suppl 1):23-6. (PMID: 10693916)
Front Syst Neurosci. 2015 Dec 18;9:173. (PMID: 26733825)
Diabetes Care. 2001 May;24(5):801-2. (PMID: 11347732)
J Vis Exp. 2017 Aug 30;(126):. (PMID: 28892027)
Biomed Res Int. 2014;2014:249031. (PMID: 25050332)
Diabetes Care. 2009 Jan;32 Suppl 1:S62-7. (PMID: 19118289)
Anat Sci Int. 2020 Jun;95(3):342-355. (PMID: 32006225)
Biomed Res Int. 2013;2013:752870. (PMID: 24151620)
Neuroimage. 2001 Dec;14(6):1337-47. (PMID: 11707089)
Neurosci Lett. 2012 Aug 8;523(1):45-9. (PMID: 22732450)
Diabetes Res Clin Pract. 1991;14 Suppl 2:S21-36. (PMID: 1794262)
J Assoc Physicians India. 1993 Jun;41(6):367-8. (PMID: 8005974)
Neurology. 1999 Dec 10;53(9):1937-42. (PMID: 10599761)
J Pharm Pharmacol. 2005 Dec;57(12):1575-80. (PMID: 16354401)
Diabetes Metab Syndr. 2018 Nov;12(6):893-896. (PMID: 29887517)
Nat Protoc. 2006;1(1):7-12. (PMID: 17406205)
Behav Brain Res. 2012 Jul 1;232(2):335-47. (PMID: 22490364)
Drugs. 2002;62(9):1357-64; discussion 1365-6. (PMID: 12076188)
Diabet Med. 1998 Jul;15(7):539-53. (PMID: 9686693)
An Acad Bras Cienc. 2019 Mar 21;91(1):e20180314. (PMID: 30916157)
Biomed Res Int. 2016;2016:7208429. (PMID: 27195294)
Sci Rep. 2018 Aug 1;8(1):11579. (PMID: 30069031)
Metabolism. 1998 Aug;47(8):977-81. (PMID: 9711995)
J Neurophysiol. 2017 Apr 1;117(4):1785-1796. (PMID: 28148640)
Behav Brain Res. 2020 Feb 3;379:112359. (PMID: 31733313)
فهرسة مساهمة: Keywords: Biomolecules; Brain activities; Diabetes type-2; Gliclazide; Neurobehaviour; Streptozotocin
تواريخ الأحداث: Date Created: 20220624 Latest Revision: 20220716
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9210456
DOI: 10.1016/j.ibneur.2022.04.001
PMID: 35746981
قاعدة البيانات: MEDLINE
الوصف
تدمد:2667-2421
DOI:10.1016/j.ibneur.2022.04.001